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Glycomacropeptide: long-term use and
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and nutritional status in children with PKU
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Abstract: In phenylketonuria, casein glycomacropeptide (CGMP) requires modification with the addition of some
essential and semi essential amino acids to ensure suitability as a protein substitute. The optimal amount and ratio
of additional amino acids is undefined.
Aim: A longitudinal, parallel, controlled study over 12months evaluating a CGMP (CGMP-AA2) formulation compared
with phenylalanine-free L-amino acid supplements (L-AA) on blood Phe, Tyr, Phe:Tyr ratio, biochemical nutritional status
and growth in children with PKU. The CGMP-AA2 contained 36mg Phe per 20 g protein equivalent.
Methods: Children with PKU, with a median age of 9.2 y (5-16y) were divided into 2 groups: 29 were given CGMP-AA2,
19 remained on Phe-free L-AA. The CGMP-AA2 formula gradually replaced L-AA, providing blood Phe concentrations
were maintained within target range. Median blood Phe, Tyr, Phe:Tyr ratio and anthropometry, were compared within
and between the two groups at baseline, 26 and 52 weeks. Nutritional biochemistry was studied at baseline and
26 weeks only.
Results: At the end of 52 weeks only 48% of subjects were able to completely use CGMP-AA2 as their single source of
protein substitute. At 52 weeks CGMP-AA2 provided a median of 75% (30–100) of the total protein substitute with the
remainder being given as L-AA. Within the CGMP-AA2 group, blood Phe increased significantly between baseline and
52 weeks: [baseline to 26 weeks; baseline Phe 270 μmol/L (170–430); 26 weeks, Phe 300 μmol/L (125–485) p = 0.06;
baseline to 52 weeks: baseline, Phe 270 μmol/L (170–430), 52 weeks Phe 300 μmol/L (200–490), p < 0.001)]. However,
there were no differences between the CGMP-AA2 and L-AA group for Phe, Tyr, Phe:Tyr ratio or anthropometry at any
of the three measured time points. Within the CGMP-AA2 group only weight (p = 0.0001) and BMI z scores (p = 0.0001)
increased significantly between baseline to 52 weeks. Whole blood and plasma selenium were significantly higher
(whole blood selenium [p = 0.0002]; plasma selenium [p = 0.0007]) at 26 weeks in the CGMP-AA2 group compared L-AA.
No differences were observed within the L-AA group for any of the nutritional markers.
Conclusions: CGMP-AA increases blood Phe concentrations and so it can only be used partly to contribute to protein
substitute in some children with PKU. CGMP-AA should be carefully introduced in children with PKU and close
monitoring of blood Phe control is essential.
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Introduction
The composition, balance and ratio of amino acids in
protein substitutes for phenylketonuria (PKU) requires
further consideration and study. Protein substitutes not
only provide 50–80% of the total nitrogen supply for
growth; they also have a number of physiological proper-
ties potentially influencing phenylalanine (Phe) concen-
trations and anabolism [1, 2]. The delivery of amino
acids (AA) into the systemic circulation alters their
plasma ratio affecting the uptake of AA at both brain
[3–5] and gut membranes [6]. Protein substitutes also
contain higher amounts of leucine compared with cow’s
milk protein (mean amount per 10 g protein equivalent:
L-AA, 127mg ± 23mg; cow’s milk, 100 ± 10mg). Leucine
stimulates muscle protein synthesis and anabolism by
activation of a complex pathway involving mTOR (mam-
malian target of rapamycin), which stimulates insulin se-
cretion [7]. However, there is evidence that L-AA are
absorbed more rapidly than intact protein sources that
requires digestion leading to less AA retention [8, 9]
whereas low Phe glycomacropeptide (CGMP) containing
a peptide component may be more efficacious [10].
CGMP is a ‘residue’ peptide found in the extracted whey
component of cheese. Although it is high in some large
neutral amino acids (LNAA) such as threonine and iso-
leucine, it is low in several essential AA and tyrosine, and
so requires supplementation to ensure suitability for use
in PKU.
Protein substitutes are essential in the management of
PKU, but the majority are based on mono amino acids.
Some children struggle accepting the taste, smell and
prescribed daily volume, while others complain of abdom-
inal discomfort and bad breath. CGMP a peptide-based
substitute with added amino acids offers an alternative
choice to the traditional mono amino acid substitutes.
Identifying suitable alternative protein substitutes with
acceptable palatability and improved biological efficacy is
important in the treatment of PKU.
Commercial CGMP protein substitutes (supplemented
with L-amino acids) (CGMP-AA) contain at least 36mg
of Phe per 20 g protein equivalent (Vitaflo International
Ltd.). We have previously reported the impact of CGMP-
AA1 on blood Phe concentrations in a group of children
aged 5–16 years of age using a formula containing 30mg
of Phe per 20 g protein equivalent [11]. Although, the
blood Phe concentrations remained within the target
reference range, they increased significantly compared
with a control group who remained on L-AA. Therefore,
we concluded that CGMP-AA1 could only partially
replace the L-AA in most children. We also considered
that the blood Phe control might be improved by using a
CGMP-AA with a higher concentration of some essential
and conditionally essential AA comparable to conventional
L-AA supplements. Therefore, we made small adjustments
to the AA formulation of the CGMP-AA, so they were
similar in profile to conventional L-AA supplements.
In this paper, we explain the changes made to the AA
profile of a CGMP-AA formula and the impact this had
on blood Phe, Tyr, and Phe:Tyr ratio. As CGMP has not
been extensively used as a protein substitute in children,
we also investigated changes in the biochemical nutri-
tional status and growth in children using modified
CGMP-AA compared to conventional protein sub-
stitutes. Therefore, in a 12-month longitudinal, prospect-
ive study, we describe the impact of using this modified
CGMP-AA formulation (CGMP-AA2) compared with a
control group of children taking conventional Phe-free
L-AA supplements only.
Methods
Subjects
Fifty children (28 boys, 22 girls) with PKU were re-
cruited. Their median age at recruitment was 9.2 years
(range 5-16y). Forty-seven children were European and
3 were of Pakistani origin. Inclusion criteria included:
diagnosed by newborn screening, aged 5 to 16 years, not
treated with sapropterin dihydrochloride, known adher-
ence with protein substitute, and 70% of blood Phe con-
centrations within Phe target range for 6 months prior
to study entry. Target blood Phe ranges for children aged
5 to 12 years were < 360 μmol/L and for 12 years and
older < 600 μmol/L according to the European guideline
recommendations [12]. Based on untreated blood Phe
levels at newborn screening and dietary Phe tolerance,
two children in the CGMP-AA2, and one child in the
L-AA group had mild PKU with the majority having
classical PKU.
The study was registered by the Health Research
Authority and was given a favourable ethical opinion
by the South Birmingham Research Ethical Committee.
Written informed consent was given for all subjects by at
least one caregiver with parental responsibility and written
assent was obtained from the subjects if appropriate for
their age and level of understanding.
CGMP-AA formulations (Table 1)
CGMP-AA2 is a berry or vanilla flavoured powdered pro-
tein substitute containing 20 g of protein equivalent, and
36mg of Phe per 35 g sachet. Each sachet was mixed with
120ml of water or phenylalanine-free milk replacement.
CGMP-AA2 was modified following the findings of a
pilot study in which CGMP-AA1 was used. Additional
Tyr, tryptophan, leucine and histidine (but less methio-
nine and lysine) were added to provide a similar AA
profile to conventional Phe-free L-AA supplements. For
each 1 g of protein equivalent, it contained 112 mg Tyr,
20 mg tryptophan, 150 mg leucine, and 35mg histidine.
Lysine and methionine were reduced compared with
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Table 1 The nutrient composition of CGMP-AA1 and CGMP-AA2 compared with conventional Phe-free L-AA
Nutrients Units CGMP-AA1 CGMP-AA2 Phe-free L-AA*
Pilot study Week 0–26 Week 0–52 Week 0–52
Per 100 g Per 20 g PE sachet Per 100 g Per 20 g PE sachet Per 100 ml Per 20 g PE pouch
Calories Kcal 342 120 342 120 71 124
Protein equivalent g 57.1 20 57.1 20 11.5 20
Total Carbohydrate g 18.6 6.5 18.6 6.5 5.4 9.4
Sugars g 6.3 2.2 6.3 2.2 4.5 7.8
Total Fat g 4.3 1.5 4.3 1.5 0.4 0.7
DHA mg 240 84 240 84 77 134
AA mg – – – – – –
Fibre g 0 0 0.3 0.1 – –
Salt g 1.5 0.53 1.5 0.53 0.25 0.43
Vitamins and minerals
Vitamin A μg RE 809 283 809 283 160 278
Vitamin D μg 12.9 4.5 12.9 4.5 5.8 10
Vitamin E mg αTE 18.6 6.5 18.6 6.5 3 5.2
Vitamin C mg 109 38 109 38 21 36
Vitamin K μg 100 35 100 35 19 34
Thiamine mg 1.9 0.68 1.9 0.68 0.4 0.7
Riboflavin mg 2.2 0.78 2.2 0.78 0.44 0.77
Niacin mg 24 8.4 24 8.4 4.8 8.4
Vitamin B6 mg 2.9 1.0 2.9 1.0 0.5 0.9
Folic Acid μg 389 136 389 136 77 134
Vitamin B12 μg 4.6 1.6 4.6 1.6 0.9 1.6
Biotin μg 183 63.9 183 63.9 36 63
Pantothenic acid mg 7.7 2.7 7.7 2.7 1.5 2.6
Choline mg 583 204 583 204 115 201
Sodium mmol 25.8 9.0 25.8 9.0 4.2 7.3
Potassium mmol 19.3 6.8 19.3 6.8 4.5 7.9
Chloride mmol 0.6 0.2 0.6 0.2 3.9 6.8
Calcium mg 1163 407 1163 407 230 400
Phosphorus mmol 34.2 12 34.2 12 6.6 11.4
Magnesium mg 366 128 366 128 72 125
Iron mg 20.9 7.3 20.9 7.3 4.2 7.3
Copper μg 2137 748 2137 748 420 730
Zinc mg 20.9 7.3 20.9 7.3 4.2 7.3
Manganese mg 3.1 1.1 3.1 1.1 0.6 1
Iodine μg 245 85.7 245 85.7 49 84
Molybdenum μg 140 49 140 49 28 48
Selenium μg 85.4 29.9 85.4 29.9 17 29
Chromium μg 85.4 29.9 85.4 29.9 17 29
L-amino acids
L-Alanine g 2.17 0.76 2.23 0.78 0.53 0.92
L-Arginine g 2.86 1.00 2.71 0.95 0.86 1.5
L-Aspartic Acid g 5.83 2.04 3.20 1.12 1.36 2.37
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CGMP-AA1 but still provided minimum amino acid re-
quirements suggested by the WHO/FAO/UNU 2007 [13].
A further difference in the formulation of CGMP-AA2,
was the residual Phe content. Due to the manufacturing
process of CGMP, there was a 17% increase in residual
Phe and CGMP-AA2 contained 36mg Phe compared to
CGMP-AA1 containing 30mg Phe for every 20 g protein
equivalent. No changes were made to the composition of
carbohydrate, fat and micronutrients of the CGMP-AA2
throughout the study. Vitaflo International Ltd. produced
the CGMP-AA2 study formulation.
Control group
Children in the control group remained on their usual
Phe-free L-AA, during the study period, with no changes
to the AA formulations throughout the study.
Selection into control or CGMP-AA2 group
Children chose the product they preferred: CGMP-AA2
or Phe-free L-AA. They remained on this formula and in
these groups for the duration of the study.
Study design (Fig. 1)
After completion of the pilot study, and following the
changes made to the CGMP formulation, a total of 50 chil-
dren were recruited and followed up for 12months. This
paper reports the prospective results of Phe and Tyr blood
concentrations, Phe:Tyr ratio, nutritional biochemistry and
growth (weight, height and BMI z scores) over 12months,
using modified CGMP-AA2 compared to Phe-free L-AA
protein substitutes. At baseline and 26weeks, morning
fasted pre-prandial venous samples were collected for nutri-
tional markers. Anthropometry, height and weight together
with a stock check of protein substitute usage, diet history,
and food frequency questionnaire were collected monthly.
All baseline measurements were collected when the children
were on Phe-free L-AA. Baseline data for Phe and Tyr blood
concentrations, and Phe:Tyr ratio were calculated as a me-
dian value from the previous 12months before study com-
mencement. Data for anthropometry and nutritional
biochemistry were collected at the start of the study.
Titration of CGMP-AA2 in the diet
Taking into consideration that CGMP-AA2 contained
Phe (36 mg for each 20 g protein equivalent), the dose of
CGMP-AA2 was individually prescribed and titrated
with the blood Phe concentrations. In the CGMP-AA2
group all the children started with a minimum of 20 g of
protein equivalent from CGMP-AA2, with Phe-free
L-AA providing the remainder of protein substitute
intake. If blood concentrations were stable or decreased,
CGMP-AA2 was increased by 20 g per day protein
equivalent reducing the Phe-free L-AA by the same
amount of protein. If there was any suggestion that
blood Phe control deteriorated (criteria blood Phe ≥ tar-
get range for 3 consecutive weeks), the dose of CGMP–
AA2 was reduced, with a concomitant increase in
Phe-free L-AA providing the remaining total protein
Table 1 The nutrient composition of CGMP-AA1 and CGMP-AA2 compared with conventional Phe-free L-AA (Continued)
Nutrients Units CGMP-AA1 CGMP-AA2 Phe-free L-AA*
Pilot study Week 0–26 Week 0–52 Week 0–52
Per 100 g Per 20 g PE sachet Per 100 g Per 20 g PE sachet Per 100 ml Per 20 g PE pouch
L-Cystine g 0.03 0.01 0.03 0.01 0.35 0.61
L-Glutamine g 7.11 2.49 7.34 2.57
Glycine g 7.91 2.77 3.43 1.2 1.35 2.35
L-Histidine g 1.20 0.42 2.00 0.7 0.53 0.92
L-Isoleucine g 3.91 1.37 3.86 1.35 0.93 1.62
L-Leucine g 3.71 1.30 8.57 3.00 1.46 2.54
L-Lysine g 3.06 1.07 2.29 0.80 0.96 1.67
L-Methionine g 1.54 0.54 0.80 0.28 0.26 0.45
L-Phenylalanine g 0.09 0.03 0.09 0.03 – –
L-Proline g 4.31 1.51 4.34 1.52 0.97 1.69
L-Serine g 2.80 0.98 2.74 0.96 0.6 1.04
L-Threonine g 6.20 2.17 6.29 2.2 0.93 1.62
L-Tryptophan g 0.49 0.17 1.14 0.40 0.29 0.5
L-Tyrosine g 2.89 1.01 6.40 2.24 1.37 2.38
L-Valine g 3.23 1.13 3.11 1.09 1.07 1.86
*protein substitute based on 20 g PE of PKU Cooler 20 (Vitaflo International Ltd)
§ L- Phenylalanine, CGMP-AA1 0.086g /100g; 0.030g/20g PE (30mg /sachet) CGMP-AA2 0.100g/100g; 0.036g/20g PE (36mg/sachet)
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equivalent requirement. No change or reduction was
made to the dietary Phe intake of subjects on the
CGMP-AA2.
Nutritional markers
At baseline and 26 weeks, a fasting morning venous blood
sample was collected and analysed for zinc, selenium
(plasma and whole blood), calcium, magnesium, phos-
phate, C-reactive protein (CRP) haemoglobin, MCV (mean
cell volume), ferritin, vitamin B12 and 25-hydroxy vitamin
D. The laboratory received all samples within 30min of
collection preventing any deterioration in sample quality.
All the samples were stored under appropriate conditions
and then measured at the same time point, minimising
laboratory variations in measurement techniques.
Zinc and selenium (whole blood and plasma) were
collected in a lithium heparin ‘trace metal’ tube and ana-
lysed using inductively coupled plasma mass spectro-
metry. Vitamin D was measured as a clotted sample via
mass spectrometry. Calcium, magnesium, phosphate, and
CRP were all measured in zinc free lithium heparin tubes
and measured on a Roche photometric analyser. Ferritin
and vitamin B12 were collected in Vacuette Z serum
clotted activator tubes and analysed by an Access
analyser using electroluminescence. Haemoglobin and
MCV were collected into EDTA tubes and measured
on a Sysmex XN 2000 analyser.
Blood Phe/Tyr monitoring
Throughout the study, trained caregivers collected weekly
early morning fasted blood spots at home. Blood specimens
were sent via first class post to the laboratory at
Birmingham Children’s Hospital. Blood samples were
collected on filter cards, Perkin Elmer 226 (UK Standard
NBS). All the cards had a standard thickness and the
blood Phe and Tyr concentrations were calculated on a
3.2 mm punch by MS/MS tandem mass spectrometry.
Anthropometry, dietary recall and monitoring
Monthly weight and height measurements were col-
lected using portable Seca scales and stadiometer. A
mean of three readings were taken and measured to one
decimal point. Home visits were completed monthly,
collecting a dietary history and food frequency question-
naire, together with adherence monitoring of protein
substitute usage by performing a stock check of the
amount of protein substitute used. Three trained dieti-
tians measured and assessed the children each month.
Statistics
Comparisons of Phe data across time were carried out
using a linear mixed models approach, which account
for both within and between subject levels of variance.
Models are constructed which include terms for ‘time’
(Baseline, 26 weeks and 52 weeks), treatment effect
(CGMP-AA2 and L-AA) and their interaction. The sub-
ject identifier is included as a random effect. Phe is
included on the square root scale to ensure normality of
model residuals. Results are presented in terms of the
mean effect at each time point with associated 95% con-
fidence intervals. Differences between time points and
Fig. 1 Diagrammatic scheme showing recruitment and introduction of CGMP-AA2 and Phe-free L-AA
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groups are obtained using analysis of deviance tables. All
analyses are carried out using programme R (Version 3).
Statistical analysis for nutritional biochemistry and
anthropometrics was performed within the groups
using non-parametric Wilcoxon matched pairs signed
rank test. When comparisons were made between the
groups non-parametric Mann Whitney test was per-
formed. Nutritional parameters were measured at base-
line and 26 weeks only, anthropometry at baseline, 26
and 52 weeks.
Results
Subjects
Of the 50 recruited children, 31 were in the CGMP-AA2
group and 19 in the L-AA control group. Prior to the
study start: 6 subjects took powdered protein substitutes
[XP Maxamum (Nutricia Ltd.), n = 1; PKU Anamix first
spoon (Nutricia Ltd.), n = 3; PKU gel (Vitaflo Inter-
national Ltd.), n = 2]; and 44 subjects took liquid
pouches [PKU Lophlex LQ (Nutricia Ltd.), n = 3; PKU
Cooler (Vitaflo International Ltd.), n = 41]. In the L-AA
group, they either received liquid pouches [PKU Lophlex
LQ (Nutricia Ltd.), n = 2; PKU Cooler (Vitaflo Inter-
national Ltd.), n = 14] or powdered preparations [PKU
gel (Vitaflo International Ltd.), n = 3]. At the start of the
study, the median age was 8.4 years (5–16) in the
CGMP-AA2 group, and 11.1 years (5–15) in the L-AA
group. Median Phe concentrations at baseline for
CGMP-AA2 were 270 μmol/L (170–430) and for L-AA,
315 μmol/L (140–600).
The total median daily dose of protein equivalent before
and throughout the study in both groups for protein sub-
stitute was 60 g/day (range, 40-60 g). The median number
of prescribed protein exchanges was 5 g protein/day
(range 3-30 g) or 250mg Phe (range, 150-1500mg).
Subject withdrawal
One boy and one girl (aged 12 years) in the CGMP-AA2
group were withdrawn from the study, both failed to com-
ply with the study protocol, one failing to return blood
Phe samples and both had poor adherence with a low Phe
diet. A total of 48 children completed the study; 29 in the
CGMP-AA2 and 19 in the Phe-free L-AA group.
Comparison of blood Phe, Tyr, Phe:Tyr ratio
between CGMP-AA2 and Phe-free L-AA groups and
within groups at: baseline, week 26 and 52 (Tables 2,
3, 4) [Additional file 1. This file shows four additional di-
agrams, Figures S1A, B, C and S2. Supplementary
figures show a mixed linear model for phe, tyr and phe:
tyr ratio at baseline, 26 and 52 weeks for all subjects,
and Fig. 2 shows phe for subjects< 12 y].
For each group the median Phe and Tyr values were
calculated for each subject over a time period from base-
line to week 26, and from week 27 to 52. The median of
the collective medians has been reported.
Blood Phe levels
Phe levels are consistently higher in the L-AA group com-
pared with the CGMP-AA2 group. Both groups observed
a rise in Phe levels over time, but this rise was more
pronounced in the CGMP-AA2 group with a statistical
difference between baseline and 52 weeks (p < 0.001).
Blood Tyr levels
Whilst Tyr levels were consistently higher in the
CGMP-AA2 groups, there were no significant differences
between the CGMP-AA2 and L-AA groups and no dif-
ferences in the change in Tyr over time.
Phe: Tyr ratio
For the CGMP-AA2 group there was a small but con-
sistent rise in the Phe:Tyr ratio with the difference
between baseline and 26 weeks (p = 0.010) and baseline
and 52 weeks (p < 0.001) both statistically significant.
Changes in the Phe:Tyr ratio in the L-AA group were
not statistically significant.
Sub- group analysis for children < 12 years of age
(Table 5) [Additional file 1]
We compared blood Phe concentrations over the same
time period in children aged < 12 years in both groups.
There were 25 children in the CGMP-AA2 group (me-
dian age 8.9y), and 9 children in the Phe-free L-AA
group (median age 9.2y). There were no significant
differences between the groups for median blood Phe at
baseline, 26 or 52 weeks. However, a significant difference
Table 2 Changes in the median (range) blood Phe concentrations (μmol/L) within and between the CGMP-AA2 and Phe-free L-AA
group at baseline, 26 and 52 weeks
Group Number of subjects Baseline μmol/L (range) Wk 26 μmol/L (range) Wk 52 μmol/L (range) P value
CGMP-AA2 29 270 §* (170–430) 300§ (125–485) 300* (200–490) §p = 0.06 *p = < 0.0011
Phe-free L-AA 19 315 §§** (140–600) 325§§ (180–580) 340** (190–600) §§P = 0.687 **p = 0.236
Wilcoxon test § GMP baseline to 26 wk., * GMP baseline to 52 wk
Wilcoxon test §§ L-AA baseline to 26 wk., ** L-AA baseline to 52 wk
ABREVIATIONS: CGMP-AA low phenylalanine glycomacropeptide protein substitute supplemented with L-amino acids, Phe-free L-AA Phenylalanine free L-amino
acid supplement
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was observed for median blood Phe in the CGMP-
AA2 group between baseline and week 26 (p = 0.022)
and baseline and week 52 (p = 0.010). No differences
were observed at any time point in the Phe-free
L-AA group.
Anthropometry (Fig. 3)
Comparison of weight, height and BMI z scores between the
CGMP-AA 2 and Phe-free L-AA groups and within groups at:
Baseline, week 26 and 52
There was no statistical significance for median weight,
height or BMI between the CGMP-AA2 and L-AA
group at each of the measured time points. However,
in the CGMP-AA2 group a significant increase was ob-
served for median (range), weight z score from base-
line (0.55, − 1.93-2.34) to week 52 (0.77, − 1.75-2.60),
(p = < 0.0001) and BMI z score from baseline (0.58,
range − 0.88-2.83) to week 52 (0.92 range, − 0.67-2.98),
(p = < 0.0001). A significant increase was also observed
from week 26 (0.53 range, − 1.8-2.47) to 52 (0.77,
range − 1.75-2.60) for weight z score (p = < 0.0001), and
BMI z score between week 26 (0.61, range − 1.9-2.81)
and week 52 (0.92 range, − 0.67-2.98) (p = < 0.0001).
In the Phe-free L-AA group there was no significant
differences for median weight or BMI z scores: base-
line to week 52 (weight z score: [p = 0.11]; BMI z
score, [p = 0.14]) or from 26 to 52 weeks: (weight z
score, [p = 0.80]; BMI z score, [p = 0.32]). However, at
baseline the control group had a median weight,
height and BMI that were nearly double that of the
CGMP-AA2 group.
Nutritional biochemistry (Table 6)
Comparison of nutritional biochemistry between the CGMP-
AA2 and Phe-free L-AA groups and within groups at
baseline and 26 weeks
The median values for all nutritional parameters mea-
sured at baseline and 26 weeks were all within the refer-
ence ranges. One exception, in both groups was vitamin
B12, which was higher than the reference range at 26
weeks. No differences were found between any of the
parameters at baseline when all the children were taking
Phe-free L-AA.
Whole blood and plasma selenium were significantly
higher (whole blood selenium [p = 0.0002]; plasma selen-
ium [p = 0.0007]) at 26 weeks in the CGMP-AA2 group
compared L-AA.
Within the CGMP-AA2 group between baseline and
week 26, whole blood and plasma selenium significantly
increased (whole blood selenium [p = < 0.0001]; plasma
selenium [p = 0.0005]) and ferritin decreased (p = 0.0006).
Median values all remained within the reference ranges.
Discussion
This is the first longitudinal, comparative prospective
study over 12 months reporting the use of CGMP-AA2
compared to conventional protein substitute L-AA in
children with PKU. After 12 months of using the modi-
fied CGMP-AA2 there were no differences for Phe, Tyr,
Phe:Tyr ratio and anthropometry compared to the con-
trol group using L-AA. However, in the same period
within the CGMP-AA2 group, blood Phe concentrations
significantly increased although this was only by
30 μmol/L. When comparing children < 12 years of age,
Table 3 Changes in the median (range) blood Tyr concentrations (μmol/L) within and between the CGMP-AA2 and Phe-free L-AA
group at baseline, 26 and 52 weeks
Group Number of subjects Baseline μmol/L (range) Wk 26 μmol/L (range) Wk 52 μmol/L (range) P value
CGMP-AA2 29 50§* (30–180) 50§ (30–210) 50* (30–170) §p = 0.916 *p = 0.239
Phe-free L-AA 19 40§§** (40–100) 40§§ (30–105) 40** (30–80) §§p = 0.672 **p = 0.111
Wilcoxon test § GMP baseline to 26 wk., * GMP baseline to 52 wk
Wilcoxon test §§ L-AA baseline to 26 wk., ** L-AA baseline to 52 wk
ABREVIATIONS: CGMP-AA low phenylalanine glycomacropeptide protein substitute supplemented with L-amino acids, Phe-free L-AA Phenylalanine free L-amino
acid supplement
Table 4 Changes in the median (range) blood Phe:Tyr ratio within and between the CGMP-AA2 and Phe-free L-AA group at
baseline, 26 and 52 weeks
Group Number of subjects Baseline (range) Wk 26 (range) Wk 52 (range) P value
CGMP-AA2 29 5.7§* (1.5–11) 6.4§ (1.3–11.7) 6.4* (1.7–11.5) §p = 0.010 *p < 0.010
Phe-free L-AA 19 7.2§§** (3.1–15) 6.8§§ (3–11.7) 7.4** (4–15.1) §§p = 0.555 **p = 0.246
Wilcoxon test § GMP baseline to 26 wk., * GMP baseline to 52 wk
Wilcoxon test §§ L-AA baseline to 26 wk., ** L-AA baseline to 52 wk
ABREVIATIONS: CGMP-AA low phenylalanine glycomacropeptide protein substitute supplemented with L-amino acids, Phe-free L-AA Phenylalanine free L-amino
acid supplement
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within the CGMP-AA2 group, the same small but con-
sistent significant increase for blood Phe concentrations
were evident. Weight and BMI z scores significantly in-
creased within the CGMP-AA2 group. Plasma and whole
blood selenium improved although ferritin decreased but
all nutritional measurements remained within the refe-
rence ranges. Identifying the reason for these physical and
biochemical changes over 12months in the CGMP-AA2
group is important to assess the suitability of using
CGMP-AA2 as a protein substitute in children with PKU.
We have previously reported a small but significant
increase in blood Phe concentrations in the first group
of children recruited to the pilot study using CGMP-
AA1 [11]. CGMP-AA1 was based on an AA profile that
met the minimum safe levels of amino acid intake
(WHO/FAO/UNU 2007) [13] for Tyr, tryptophan, leu-
cine, and histidine. CGMP-AA1 contained 30mg of Phe
for every 20 g protein equivalent. A modified CGMP-AA
formula (CGMP-AA2) was produced by making small
adjustments to the AA composition of CGMP-AA1,
increasing some of the LNAA (Tyr, tryptophan, leucine
and histidine) in amounts similar to conventional L-AA
supplements. Although in this study, we examined a
different cohort of children, after using CGMP-AA2 for
12months, blood Phe concentrations, were lower than
those in the pilot study using CGMP-AA1. Median Phe
concentrations at the end of the pilot study 317 μmol/L
compared to CGMP-AA2 after 12months Phe 300 μmol/L.
We were also able to increase the amount of protein
equivalent supplied from CGMP-AA2 to 75% of total
protein equivalent, without any reduction in dietary
Phe intake. However, at the end of this study period,
only 14 of 29 children (48%) were able to fully transi-
tion to CGMP-AA2 as their only protein substitute,
which suggests that the residual Phe concentration
present in CGMP-AA2 still increases blood Phe concen-
trations in children.
Identifying the optimal amino acid profile for pro-
tein substitutes is challenging, although, the ratio and
amount of LNAA appears important. It is suggested
that LNAA supplementation competes with Phe up-
take at the gut and blood brain barrier (BBB): LNAA
cross the intestinal mucosa using a carrier protein
similar to that at the BBB [14–16]. In vitro studies
investigating intestinal epithelial transport of amino
acids, indicate that lysine, histidine, leucine and Tyr
significantly reduce Phe uptake [6]. High concentra-
tions of LNAA compete with the transport of Phe at
Table 5 Changes in the median (range) blood Phe concentrations (μmol/L) within and between the CGMP-AA2 and Phe-free L-AA
group at baseline, 26 and 52 weeks for children < 12 years
Group Number of subjects Baseline μmol/L (range) Wk 26 μmol/L (range) Wk 52 μmol/L (range) P value
CGMP-AA2 25 270 §* (170–360) 300§ (125–415) 290* (200–450) §p = 0.04 *p = 0.04
Phe-free L-AA 9 288 §§** (140–470) 287§§ (180–348) 291* (190–344) §P = 0.90 **p = 0.41
Wilcoxon test § GMP baseline to 26 wk., * GMP baseline to 52 wk
Wilcoxon test §§ L-AA baseline to 26 wk., ** L-AA baseline to 52 wk
ABABBREVIATIONS: CGMP-AA low phenylalanine glycomacropeptide protein substitute supplemented with L-amino acids, Phe-free L-AA Phenylalanine free L-amino
acid supplement
Fig. 2 Measured Phe levels in children < 12 years of age in the CGMP-AA and L-AA groups and mean 95% confidence intervals
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the gut cellular membrane and may decrease blood
Phe concentrations. Additionally LNAA supplementa-
tion has been shown to reduce blood and brain Phe
concentrations [17, 18] and restore some of the dis-
turbed Phe transport across the BBB by altering
monoaminergic neurotransmitter concentrations. In
mice studies, mice chow with added LNAA, improved
brain tryptophan, serotonin and norepinephrine con-
centrations [4]. There are other functional effects of
protein substitutes, which indirectly affect blood Phe
concentrations. These include the rate of delivery of
L-AA into the systemic circulation and muscle protein
anabolism. Amino acids play an important, but as yet
not fully understood role in nutritional signalling and
regulation of multiple cellular processes [19]. Leucine,
is a potential insulin secretagogue when administered
with carbohydrate and protein, acting as a pharmaco-
nutrient AA improving muscle protein synthesis, by
stimulating mRNA changes via insulin independent
and dependent pathways [7, 20]. Van Loon et al. maxi-
mised endogenous insulin secretion by the combined
ingestion of carbohydrate and wheat protein hydrolys-
ate, with added leucine and Phe [21]. In vitro studies,
using incubated β cells of the pancreas, have shown
that arginine, leucine and phenylalanine have a strong
insulinotropic effect [22]. Further studies are needed
to maximize our understanding of the physiological
absorption process of AA protein substitutes, with the
goal, to achieve a normal absorption pattern compar-
able to natural intact protein.
In contrast, many L-AA are bitter tasting and unpleas-
ant to take, particularly leucine, tryptophan and histidine
[23, 24]. By adding more of these AA to CGMP-AA for-
mulations, it potentially decreases their acceptability and
palatability. It has been suggested by Van Calcar [25]
that the AA profile in CGMP-AA should provide 130 to
150% of the 2002 Institute of Medicine American dietary
reference intake for histidine, leucine, methionine, tryp-
tophan and Tyr to compensate for faster absorption and
degradation of AA [26].
In our study, 52% of children in the CGMP-AA2
group were prescribed a combination of CGMP-AA2
and separate Phe-free L-AA supplements, as they could
not fully transition onto CGMP-AA2 in order to main-
tain blood Phe concentrations within the target range of
120 to 360 μmol/L. The median amount of protein sub-
stitute provided by CGMP-AA2 that could be tolerated
without affecting blood Phe control was 75% of the total
amount. This contrasts with other researchers findings
that have reported that the Phe content of CGMP-AA
has little effect on blood Phe concentration. In an
uncontrolled, short term study reported in 10 children
(aged 4 to 16 years) with PKU, when 50% of their total
protein requirements were supplied by ‘GMP cheese’ for
9 weeks, blood Phe concentrations decreased by a median
of 114 μmol/L although this was not statistically sig-
nificant [27]. In a short-term randomized cross over
trial in 30 patients aged 15 years or over, comparing
CGMP-AA with L-amino acid supplements only,
CGMP-AA was associated with a non-significant in-
crease in Phe of 62 ± 40 μmol/L, although 10 of the 30
patients were prescribed sapropterin (likely to have
improved Phe tolerance), 6 patients appeared less
adherent with CGMP-AA and overall subjects were
only studied over a short time and had a higher baseline
blood Phe levels in comparison to our study group [28].
Furthermore, increases of between 60 to 102 μmol/L may
be unacceptable in children particularly as evidence is
accumulating to suggest that optimal blood Phe may be
below 240 μmol/L [29].
Median nutritional blood parameters in both groups at
baseline and 26 weeks were all within reference ranges,
Fig. 3 Weight and BMI z scores for CGMP-AA2 and L-AA at baseline,
26 and 52 weeks
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with the exception on vitamin B12 being higher than the
reference range at 26 weeks in both groups. There were
no biochemical signs of vitamin or mineral deficiencies
in line with what was retrospectively reported in adult
PKU patients [30]. There was a significant increase in
whole blood and plasma selenium between the groups
at 26 weeks, and within the CGMP-AA2 group from
baseline to 26 weeks. The selenium content of both
products was similar, a median intake of 60 g protein
equivalent from Phe-free L-AA provided 87 mg of se-
lenium compared with CGMP-AA2 providing 90 mg. It
is only conjecture, but absorption of selenium in the
CGMP-AA2 group may be enhanced based on its bio-
active properties. It is also possible that CGMP may
modulate microbiota resulting in a different absorption
or bioavailability. Furthermore, whey protein is rich in
the sulfhydryl amino acid cysteine, which is a precursor
of glutathione, and may in part explain the higher se-
lenium concentrations in the CGMP-AA2 group.
Muniz-Naveiro [31] reported the largest percentage of
selenium in cow’s milk was found in the whey phase,
although unmodified CGMP is not high in cysteine or
selenium. Peptides containing isoleucine, proline, ly-
sine, glutamine, aspartic and glutamic acid have been
shown to have antioxidant properties; hence peptide
structure and amino acid sequencing influence bio-
logical function. The bioactive antioxidant properties of
CGMP and absorption in the gut may have a selenium
sparing effect compared to protein substitutes without
a peptide base [32, 33].
Weight and BMI increased significantly in the CGMP-
AA2 group with an increase in weight and BMI first
becoming evident from 26 weeks, this may be related to
some children using a protein free milk replacement to
make up their powdered CGMP-AA2 protein substitute.
A mean intake of 400ml/day of protein-free milk replace-
ment would increase energy intake by 270 kcal/day. Only
9 children were routinely adding additional milk substitute
to their CGMP-AA2 but there were no significant diffe-
rences evident between children using protein free milk or
water to prepare the CGMP-AA 2, but this may not be
apparent due to the small numbers in the group. We
changed this practice when it was observed that children
were gaining extra weight. Another consideration influen-
cing growth is age; the Phe-free L-AA group were an older
patient cohort and therefore, over the 12-month period it
is difficult to quantify how many were actively reaching
puberty and the effect this has on weight, height and BMI.
Table 6 Median nutritional biochemistry comparing CGMP-AA2 with Phe-free L-AA at baseline and week 26
Parameters Reference
range
Base-line (range) Significance
Base-line
26wk (range) Significance at 26wk
Phe-free L-AA CGMP-AA2 Phe-free L-AA CGMP-AA2
Zinc μmol/L 11–24 14.3 (12.9–
17.4)
14.4 (11.3–18.2) p = 0.3 14.55 (12.3–
17.5)
14.0 (10.5–
16.4)
p = 0.24
C reactive protein mg/L < 10 1.0 (1–4) 1.0 (1–11) p = 0.27 1.0 (1–3) 1.0 (1–6) p = 0.69
Whole blood Selenium ns 0.94 (0.76–
1.21)
0.99§ (0.48–1.38) p = 0.57 0.98* (0.75–
1.23)
1.22*§ (0.86–
1.56)
§p = < 0.0001 *p =
0.0002
Selenium μmol/L 4-7y 0.7–1.7 0.86 (0.53–1.1) 0.91§ (0.38–1.4) p = 0.57 0.85* (0.58–
1.14)
1.12*§ (0.58–
1.35)
§p = 0.0005 *p =
0.0007
7-
18y
0.62–
1.3
Calcium mmol/L 2.2–2.7 2.46 (2.33–
2.56)
2.49 (2.32–2.63) p = 0.56 2.44 (2.31–
2.59)
2.45 (2.25–
2.68)
p = 0.77
Magnesium mmol/L 0.7–1 0.84 (0.75–
0.92)
0.85 (0.72–1.0) p = 0.68 0.82 (0.72–
0.92)
0.84 (0.76–
0.92)
p = 0.14
Phosphate mmol/L 0.9–1.8 1.30 (0.94–
1.53)
1.38 (1.0–1.59) p = 0.08 1.33 (1.0–1.58) 1.39 (1.0–1.71) p = 0.20
25 hydroxy vitamin D
nmol/L
> 50 93.9 (38.8–
182.3)
95.3 (60–162) p = 0.27 84.2 (47.6–
139)
87.6 (47.9–158) p = 0.49
Haemoglobin g/L 120–140 137 (119–164) 136 (101–156) p = 0.55 141 (120–164) 135 (109–155) p = 0.23
MCV fl 78–93 82 (76–90) 82 (75–91) p = 0.48 84 (77–93) 82.5 (76–88) p = 0.50
Ferritin μg/L 11–60 32.8 (20.9–
63.1)
27.4§§ (17.9–
116.5)
p = 0.16 30.80 (17.6–
75.6)
25.2§§ (15.9–
91.6)
§§p = 0.0006
Vitamin B12ng/L 245–798 798 (390–
1500)
1088 (333–
1500)
p = 0.1 745 (308–
1500)
922 (437–
1500)
p = 0.23
ns not specified
Wilcoxon test (paired and unpaired t test)
§Whole blood and plasma selenium CGMP-AA2 baseline compared with CGMP-AA2 at 26 weeks
*Whole blood and plasma selenium CGMP-AA2 26 weeks compared with L-AA at 26 weeks
§§ Ferritin CGMP-AA2 baseline compared with CGMP-AA2 at 26 weeks
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A further consideration is that CGMP based on a protein
source may be more efficiently utilized increasing muscle
mass compared to L-AA. Longer-term observations of
both study groups will hopefully answer this question with
data describing both fat free and fat mass index.
There are several limitations to this study that need to
be considered. We were unable to conduct a randomised
controlled blind trial. CGMP-AA2 and conventional
L-AA supplements are very different in taste, texture and
appearance rendering any blind or randomised trial very
challenging in children who may not easily accept changes
to their protein substitutes [34]. In this study, 40% of chil-
dren preferred to stay on their usual Phe-free L-amino
acid supplement (control group) and so they were a
self-selected, not age-matched group and children in the
control group were older than the study group. Also in
teenage children in both study groups, ensuring dietary
adherence was difficult although patients were moni-
tored closely with monthly home visits to check stock
levels of protein substitute and dietary intake. A further
limitation was the use of low protein milk substitute to
make up the protein substitute, in addition to increa-
sing energy intake it possibly altered CGMP-AA2 absorp-
tion, affecting amino acid kinetics.
Conclusions
It is clear that the biological functions of CGMP may
potentially offer many health benefits in PKU [35–40]
and it is likely to play a significant future role in
provision of low Phe protein substitute. However, it is
important that the manufacturers of CGMP seek to re-
duce its Phe content and the formulation of
CGMP-AA2 requires further research and development
in order to ensure optimal amino acid profiling.
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